CSIMarket
 
Contrafect Corporation  (CFRX)
Other Ticker:  
 
 
Price: $0.0500 $-0.02 -27.954%
Day's High: $0.062 Week Perf: -16.39 %
Day's Low: $ 0.05 30 Day Perf: -82.45 %
Volume (M): 910 52 Wk High: $ 3.95
Volume (M$): $ 46 52 Wk Avg: $1.14
Open: $0.06 52 Wk Low: $0.04



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 11
 Employees 27
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -24
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Contrafect Corporation
Contrafect Corporation, founded in 2008, is a clinical-stage biotechnology company that uses genetic engineering technology to create innovative therapies for the treatment of infectious diseases. Its headquarters is located in Yonkers, New York, and is led by Roger Pomerantz, the CEO and President.

Contrafect's approach to fighting infectious diseases is based on targeting specific bacterial pathogens and then using their own natural defense mechanisms to destroy them. The company uses monoclonal antibodies (mAbs) as a therapeutic tool to fight against infections. These antibodies can target bacteria from inside the body and stop them from replicating, thereby helping the patientes immune system fight and eliminate the disease.

The company's lead product candidate, CF-301, is a recombinant protein that targets the bacterium Staphylococcus aureus (S. aureus) and is undergoing clinical trials. S. aureus is a major cause of hospital-acquired and community-acquired infections, including pneumonia and bloodstream infections. CF-301 is designed to be used in combination with standard-of-care antibiotics to enhance their efficacy and reduce the risk of antibiotic resistance.

Contrafect has also developed a proprietary antibody discovery platform, mAbSeqe, which uses rapid sequencing of antigen-specific B cells to discover mAbs with superior binding properties. It has several other research programs underway to discover and develop new treatments for other infectious diseases.

In addition to its research and development efforts, Contrafect has also made strategic partnerships with other companies in the pharmaceutical industry. For instance, it licensed CF-301 to UK-based pharmaceutical company, GSK, for commercialization in Europe for use in combination with other antibiotics.

Overall, Contrafect is a cutting-edge biotechnology company dedicated to developing innovative therapies to combat infectious diseases, particularly antibiotic-resistant bacteria. With a strong leadership team, a robust research pipeline, and a focus on partnership and collaboration, Contrafect is well poised to make an impact in the world of infectious disease treatment.


   Company Address: 28 Wells Avenue Yonkers 10701 NY
   Company Phone Number: 207-2300   Stock Exchange / Ticker: NASDAQ CFRX
   CFRX is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Contrafect Corporation

2. CFRX Takes a Positive Turn: Contrafect Corporation Shows Remarkable Improvement with Reduced Operating Loss

Exciting Times Ahead: CFRX Shows Promising Results in Latest Reporting Cycle
Investors and stockholders of the Contrafect Corporation (CFRX) can breathe a sigh of relief as the latest financial report for the July to September 30, 2023 period brings positive news. While expectations of any significant revenue growth were not high, the company's operating loss has seen a remarkable reduction, which bodes well for the future of CFRX.
During this reporting cycle, CFRX recorded an operating loss of $-6.677 million, a significant improvement when compared to the same period in 2022, where the operating loss stood at $-21.899 million. This notable decrease in operating losses demonstrates that Contrafect Corporation is moving in the right direction and taking steps towards financial stability.

Contrafect Corporation

Contrafect Corporation Reports Remarkable Turnaround, Slashes Operating Deficit by $12 Million in Q2 2023



Contrafect Corporation, a leading player in the Major Pharmaceutical Preparations sector, has recently released its financial results for the second quarter of 2023. The company reported an operating deficit of $-7.975 million, marking a significant improvement compared to the previous year's corresponding time frame. This article analyzes the impact of these improved financial results on Contrafect Corporation's future prospects, highlighting the potential implications for the company's growth and investor sentiment.
1. Cost-Effective Business Operations:
Contrafect Corporation demonstrated its ability to conduct business more cost-effectively during the second quarter of 2023, compared to the same period in the previous year. This considerable improvement is reflected in the reduction of the operating deficit from $-20.026 million to $-7.975 million. The company's commitment to managing expenses and optimizing operations appears to be paying off.

Contrafect Corporation

Contrafect Corporation's Financial Stability Jeopardized as Operating Deficit Skyrockets to $-8.858 Million in Q1 2023

In an unexpected move, Contrafect Corporation has experienced some major adjustments at the top-line throughout its earnings cycle from January to March 2023. This comes as a surprise to stockholders who had not anticipated such changes.
While investors have been keeping a watchful eye on the Major Pharmaceutical Preparations company's financial performance, the latest results show that the operating deficit stood at $-8.858 million during the same period. This is a significant increase compared to the same period last year, which raises concerns about Contrafect Corporation's financial stability.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com